[Impact of lipid metabolism parameters on the development and progression of coronary artery disease : An update]
- PMID: 27215419
- DOI: 10.1007/s00059-016-4430-8
[Impact of lipid metabolism parameters on the development and progression of coronary artery disease : An update]
Abstract
Disorders of lipid metabolism play a major role in the development and progression of coronary artery disease. Dyslipidemia therefore plays a central role in therapeutic approaches for prevention and treatment of cardiovascular events associated with coronary artery disease. Epidemiological studies have shown an association between various lipid metabolism parameters, the risk of developing coronary artery disease and progression of a pre-existing disease. In particular, increased levels of low-density lipoprotein cholesterol (LDL-C), reduced levels of HDL cholesterol (HDL-C), as well as high levels of triglycerides and increased lipoprotein(a) [Lp(a)] levels can be taken into account when assessing the risk stratification of patients for primary prevention of coronary artery disease. Lifestyle and dietary changes, intensified statin therapy and possibly the addition of ezetimibe remain the major interventions in both primary and secondary prevention of coronary artery disease, as they improve the prognosis particularly by lowering levels of LDL-C. Recently, genetic studies have contributed to extending our understanding of the relationship between lipid metabolism and coronary artery disease. A causal role for progression of coronary artery disease could be demonstrated for LDL-C, Lpa and triglyceride-rich lipoproteins (TRL), which could not be demonstrated for HDL-C in various studies. Furthermore, the effect of reduction of LDL-C by proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition and by the cholesteryl ester transfer protein (CETP) inhibitor anacetrapib on cardiovascular events is currently being investigated in large clinical outcome study programs.
Keywords: Coronary artery disease; Lipid metabolism; Lipoprotein(a); Proprotein covertase subtilisin-kexin type 9, human; Triglycerides.
Similar articles
-
[PCSK9 - "missing link" in familial hypercholesterolemia : New therapeutic options in hypercholesterolemia and coronary artery disease].Herz. 2016 Jun;41(4):281-9. doi: 10.1007/s00059-016-4435-3. Herz. 2016. PMID: 27215417 Review. German.
-
Effects of PCSK9 Inhibitors on Other than Low-Density Lipoprotein Cholesterol Lipid Variables.J Cardiovasc Pharmacol Ther. 2018 Jan;23(1):3-12. doi: 10.1177/1074248417724868. Epub 2017 Aug 22. J Cardiovasc Pharmacol Ther. 2018. PMID: 28826253 Review.
-
Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update.Nutr Metab Cardiovasc Dis. 2013 Sep;23(9):799-807. doi: 10.1016/j.numecd.2013.05.002. Epub 2013 Aug 9. Nutr Metab Cardiovasc Dis. 2013. PMID: 23932901 Review.
-
LDL, HDL, VLDL, and CVD Prevention: Lessons from Genetics?Curr Cardiol Rep. 2015 Jul;17(7):610. doi: 10.1007/s11886-015-0610-z. Curr Cardiol Rep. 2015. PMID: 26031673 Review.
-
PCSK9 Inhibitor causes a decrease in the level of oxidatively modified low-density lipoproteins in patients with coronary artery diseases.Ter Arkh. 2018 Sep 20;90(9):27-30. doi: 10.26442/terarkh201890927-30. Ter Arkh. 2018. PMID: 30701731
Cited by
-
[Serum annexin A2 level is significantly elevated in patients with coronary heart disease].Nan Fang Yi Ke Da Xue Xue Bao. 2020 Mar 30;40(3):382-387. doi: 10.12122/j.issn.1673-4254.2020.03.16. Nan Fang Yi Ke Da Xue Xue Bao. 2020. PMID: 32376582 Free PMC article. Chinese.
-
Case Report: Neurological adverse events in subject with myasthenia gravis after PCSK9 inhibitor administration.Front Cardiovasc Med. 2024 Mar 12;11:1343775. doi: 10.3389/fcvm.2024.1343775. eCollection 2024. Front Cardiovasc Med. 2024. PMID: 38532873 Free PMC article.
-
Pragmatic Analysis of Dyslipidemia Involvement in Coronary Artery Disease: A Narrative Review.Curr Cardiol Rev. 2020;16(1):36-47. doi: 10.2174/1573403X15666190522100041. Curr Cardiol Rev. 2020. PMID: 31113345 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous